FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ettore Seregni

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Debora Degl'Innocenti; Angela Greco; Cinzia Lanzi; Federica Perrone; Marco A Pierotti; Silvana Pilotti; Paola Romeo; Marialuisa Sensi; Ettore Seregni; Eva Tarantino; Giuliana Cassinelli; Veronica Catalano; Maria Grazia Borrello
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Carlo Chiesa; Enrico Maria Civelli; Rodolfo Lanocita; Marco Maccauro; Alfonso Marchianò; Vincenzo Mazzaferro; M Mira; C Morosi; A Negri; S Pellizzari; Raffaele Romito; Ettore Seregni; C Sposito; Carlo Spreafico; C Bampo; Sherrie Bhoori; Tiziana Camerini; M Carrara; Emilio Bombardieri
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.
maura massimino; Cristina Meazza; Federica Pallotti; Emilia Pecori; Marta Podda; Geraldina Poggi; Daniela Polastri; Bianca Pollo; Paolo Potepan; Daria Riva; Elisabetta Schiavello; Ettore Seregni; Fabio Simonetti; Filippo Spreafico; Monica Terenziani; Laura Valentini; Veronica Biassoni; Michela Casanova; Serena Catania; Graziella Cefalo; Carlo Alfredo Clerici; Paola Collini; Andrea Ferrari; Roberto Luksch; Lorenza Gandola
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ettore Seregni (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Debora Degl'Innocenti; Angela Greco; Cinzia Lanzi; Federica Perrone; Marco A Pierotti; Silvana Pilotti; Paola Romeo; Marialuisa Sensi; Ettore Seregni; Eva Tarantino; Giuliana Cassinelli; Veronica Catalano; Maria Grazia Borrello
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Endocrine-related cancer 2013;20(1):23-37.
2012: Carlo Chiesa; Enrico Maria Civelli; Rodolfo Lanocita; Marco Maccauro; Alfonso Marchianò; Vincenzo Mazzaferro; M Mira; C Morosi; A Negri; S Pellizzari; Raffaele Romito; Ettore Seregni; C Sposito; Carlo Spreafico; C Bampo; Sherrie Bhoori; Tiziana Camerini; M Carrara; Emilio Bombardieri
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2012;56(6):503-8.
2012: maura massimino; Cristina Meazza; Federica Pallotti; Emilia Pecori; Marta Podda; Geraldina Poggi; Daniela Polastri; Bianca Pollo; Paolo Potepan; Daria Riva; Elisabetta Schiavello; Ettore Seregni; Fabio Simonetti; Filippo Spreafico; Monica Terenziani; Laura Valentini; Veronica Biassoni; Michela Casanova; Serena Catania; Graziella Cefalo; Carlo Alfredo Clerici; Paola Collini; Andrea Ferrari; Roberto Luksch; Lorenza Gandola
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma.
Journal of neuro-oncology 2012;108(1):163-71.
2012: Anna Villarini; Maggiorino Barbero; Elena Bellotti; Bernardo Bonanni; Eleonora Bruno; Giuseppe Fornaciari; Rocco Galasso; Giuliana Gargano; Vittorio Krogh; Giorgio Macellari; Maria Piera Mano; Daniele Morelli; Adriana Paduos; Salvatore Panico; Patrizia Pasanisi; Milena Raimondi; Corrado Scipioni; Ettore Seregni; Milena Simeoni; Adele Traina; Elisabetta Venturelli; Franco Berrino
Lifestyle and breast cancer recurrences: the DIANA-5 trial.
Tumori 2012;98(1):1-18.
2011: Maria Grazia Borrello; Veronica Catalano; Paola Collini; Debora Degl'Innocenti; Morena Gobbo; Angela Greco; Piera Mondellini; Bernard Peissel; Marco A Pierotti; Maria Grazia Rizzetti; Antonella Aiello; Italia Bongarzone; Ettore Seregni
Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
Endocrine-related cancer 2011;18(4):519-27.
2011: maura massimino; Lorenza Gandola; Emanuele Pignoli; Ettore Seregni; Alfonso Marchianò; Emilia Pecori; Serena Catania; Graziella Cefalo
TSH suppression as a possible means of protection against hypothyroidism after irradiation for childhood Hodgkins lymphoma.
Pediatric blood & cancer 2011;57(1):166-8.
2010: Massimo Milione; Ettore Seregni
Pathological diagnosis and tumor markers.
Tumori 2010;96(5):810-6.
2010: Maria Rita Castellani; S Seghezzi; Carlo Chiesa; G L Aliberti; Marco Maccauro; Ettore Seregni; E Orunesu; R Luksch; Emilio Bombardieri
(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2010;54(1):100-13.
2010: Ettore Seregni; Marco Maccauro; Angela Coliva; Maria Rita Castellani; Emilio Bajetta; Gianluca Aliberti; C Vellani; Carlo Chiesa; Antonia Martinetti; Anna Bogni; Emilio Bombardieri
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2010;54(1):84-91.
2010: Debora Degl'Innocenti; Chiara Alberti; Giancarlo Castellano; Angela Greco; Claudia Miranda; Marco A Pierotti; Ettore Seregni; Maria Grazia Borrello; Silvana Canevari; Antonella Tomassetti
Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.
PloS one 2010;5(9):e12701.
2009: Carlo Chiesa; A Negri; C Albertini; R Azzeroni; Ernesto Setti; Luca T Mainardi; Gianluca Aliberti; Ettore Seregni; Emilio Bombardieri
A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2009;53(6):658-70.
2009: Carlo Chiesa; F Botta; Angela Coliva; Marco Maccauro; liliana devizzi; Anna Guidetti; Carmelo Carlo-Stella; Ettore Seregni; ALESSANDRO MASSIMO GIANNI; Emilio Bombardieri
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
European journal of nuclear medicine and molecular imaging 2009;36(11):1745-57.
2009: Carlo Chiesa; Maria Rita Castellani; C Vellani; E Orunesu; A Negri; R Azzeroni; F Botta; Marco Maccauro; Gianluca Aliberti; Ettore Seregni; M Lassmann; Emilio Bombardieri
Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2009;53(5):546-61.
2009: Alberto Zacchetti; Angela Coliva; Elena Luison; Ettore Seregni; Emilio Bombardieri; Augusto Giussani; Mariangela Figini; Silvana Canevari
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.
Nuclear medicine and biology 2009;36(7):759-70.
2009: maura massimino; Lorenza Gandola; Franco Mattavelli; Natalia Pizzi; Ettore Seregni; Federica Pallotti; Filippo Spreafico; Alfonso Marchianò; Monica Terenziani; Graziella Cefalo; Veronica Biassoni; Cristina Meazza; Giovanna Trecate; Paola Collini
Radiation-induced thyroid changes: a retrospective and a prospective view.
European journal of cancer (Oxford, England : 1990) 2009;45(14):2546-51.
2009: Veronica Biassoni; Federica Pallotti; Filippo Spreafico; Ettore Seregni; Lorenza Gandola; Antonia Martinetti; Emilio Bombardieri; maura massimino
A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report.
Journal of medical case reports 2009;3():17.
2008: liliana devizzi; Anna Guidetti; Corrado Tarella; Michele Magni; Paola Matteucci; Ettore Seregni; Carlo Chiesa; Emilio Bombardieri; Massimo Di Nicola; Carmelo Carlo-Stella; ALESSANDRO MASSIMO GIANNI
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5175-82.
2007: maura massimino; Lorenza Gandola; Paola Collini; Ettore Seregni; Alfonso Marchianò; Annalisa Serra; Emanuele Pignoli; Filippo Spreafico; Federica Pallotti; Monica Terenziani; Veronica Biassoni; Emilio Bombardieri; Franca Fossati-Bellani
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
International journal of radiation oncology, biology, physics 2007;69(2):404-10.
2007: Dario Baratti; Shigeki Kusamura; Antonia Martinetti; Ettore Seregni; Barbara Laterza; Daniela G Oliva; Marcello Deraco
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Annals of surgical oncology 2007;14(8):2300-8.
2007: Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Ettore Seregni; Marco Maccauro; Emilio Bombardieri
Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(3):339-42.
2007: Carlo Chiesa; Francesca Botta; Erika Di Betta; Angela Coliva; Marco Maccauro; Gianluca Aliberti; Sergio Bavusi; liliana devizzi; Anna Guidetti; Ettore Seregni; ALESSANDRO MASSIMO GIANNI; Emilio Bombardieri
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Cancer biotherapy & radiopharmaceuticals 2007;22(1):113-20.
2007: Dario Baratti; Shigeki Kusamura; Antonia Martinetti; Ettore Seregni; Daniela G Oliva; Barbara Laterza; Marcello Deraco
Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Annals of surgical oncology 2007;14(2):500-8.
2007: Marco Guzzo; Pasquale Quattrone; Ettore Seregni; Roberto Bianchi; Franco Mattavelli
Thyroid carcinoma associated with squamous cell carcinoma of the head and neck: which policy?
Head & neck 2007;29(1):33-7.
2006: Paola Collini; maura massimino; Silvia Fagundes Leite; Franco Mattavelli; Ettore Seregni; Nicola Zucchini; Filippo Spreafico; Andrea Ferrari; Maria Rita Castellani; Giulio Cantù; Franca Fossati-Bellani; Juan Rosai
Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan.
Pediatric blood & cancer 2006;46(3):300-6.
2006: maura massimino; Paola Collini; Silvia Fagundes Leite; Filippo Spreafico; Nicola Zucchini; Andrea Ferrari; Franco Mattavelli; Ettore Seregni; Maria Rita Castellani; Giulio Cantù; Franca Fossati-Bellani; Juan Rosai
Conservative surgical approach for thyroid and lymph-node involvement in papillary thyroid carcinoma of childhood and adolescence.
Pediatric blood & cancer 2006;46(3):307-13.
2005: Jinong Li; Rosaria Orlandi; C Nicole White; Jason Rosenzweig; Jing Zhao; Ettore Seregni; Daniele Morelli; Yinhua Yu; Xiao-Ying Meng; Zhen Zhang; Nancy E Davidson; Eric T Fung; Daniel W Chan
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry.
Clinical chemistry 2005;51(12):2229-35.
2005: Angela Coliva; Alberto Zacchetti; Elena Luison; Antonella Tomassetti; Italia Bongarzone; Ettore Seregni; Emilio Bombardieri; Franck Martin; Augusto Giussani; Mariangela Figini; Silvana Canevari
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
Cancer immunology, immunotherapy : CII 2005;54(12):1200-13.
2005: Veronica Huber; Stefano Fais; Manuela Iero; Luana Lugini; Paola Canese; Paola Squarcina; Annamaria Zaccheddu; Marisa Colone; Giuseppe Arancia; Massimo Gentile; Ettore Seregni; Roberta Valenti; Giuseppina Ballabio; Filiberto Belli; Ermanno Leo; Giorgio Parmiani; Licia Rivoltini
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
Gastroenterology 2005;128(7):1796-804.
2004: Antonia Martinetti; Emilio Bajetta; Leonardo Ferrari; Nicoletta Zilembo; Ettore Seregni; M Del Vecchio; Raffaella Longarini; Ignazia La Torre; Luisa Toffolatti; D Paleari; Emilio Bombardieri
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Endocrine-related cancer 2004;11(4):771-9.
2004: Paola Fierabracci; Aldo Pinchera; Massimo Tonacchera; Patrizia Agretti; Giuseppina de Marco; S Albertini; G Conforti; Ettore Seregni; Roberto Agresti; Lucia Grasso; Claudio Giani
Absence of interference of serum IgGs from patients with breast cancer and thyroid autoimmunity on the function of human iodide symporter gene stably transfected in CHO cells.
Journal of endocrinological investigation 2004;27(9):862-5.
2004: Leonardo Ferrari; Ettore Seregni; giovanni lucignani; Emilio Bajetta; Antonia Martinetti; Gianluca Aliberti; Federica Pallotti; Giuseppe Procopio; Silvia Della Torre; R Luksch; Emilio Bombardieri
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
The International journal of biological markers 2004;19(4):295-304.
2004: Leonardo Ferrari; Ettore Seregni; Gianluca Aliberti; Antonia Martinetti; Federica Pallotti; Carlo Villano; giovanni lucignani; Emilio Bombardieri
Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2004;48(3):237-42.
2004: Giuditta Cuccuru; Cinzia Lanzi; Giuliana Cassinelli; Graziella Pratesi; Monica Tortoreto; Giovanna Petrangolini; Ettore Seregni; Antonia Martinetti; Diletta Laccabue; Chiara Zanchi; Franco Zunino
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Journal of the National Cancer Institute 2004;96(13):1006-14.
2004: Emilio Bombardieri; Ettore Seregni; Carlo Villano; Arturo Chiti; Emilio Bajetta
Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2004;48(2):150-63.
2004: Ettore Seregni; Antonio Coli; Nicola Mazzucca
Circulating tumour markers in breast cancer.
European journal of nuclear medicine and molecular imaging 2004;31 Suppl 1():S15-22.
2004: Nicoletta Zilembo; Emilio Bajetta; Ettore Bichisao; Antonia Martinetti; Ignazia La Torre; Paolo Bidoli; Raffaella Longarini; Tindara Portale; Ettore Seregni; Emilio Bombardieri
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2004;58(4):255-9.
2004: Giordano Savelli; giovanni lucignani; Ettore Seregni; Alfonso Marchianò; Gianluca Serafini; Gianluca Aliberti; Carlo Villano; Marco Maccauro; Emilio Bombardieri
Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
Nuclear medicine communications 2004;25(5):445-9.
2003: Antonia Martinetti; Ettore Seregni; Leonardo Ferrari; Federica Pallotti; Gianluca Aliberti; Angela Coliva; Silvia Fracassi; Emilio Bombardieri
Evaluation of circulating calcitonin: analytical aspects.
Tumori 2003;89(5):566-8.
2003: Ettore Seregni; Federica Pallotti; Franco Mattavelli; Leonardo Ferrari; Antonia Martinetti; Gianluca Aliberti; Carlo Villano; Maria Rita Castellani; Emilio Bombardieri
Diagnostic procedures in the follow-up of patients affected by MEN type 2.
Tumori 2003;89(5):563-5.
2003: Franco Mattavelli; Ettore Seregni; Paola Collini; Barbara Pasini; Antonella Aiello; Carmen Barbaccia; Gabriella Bimbi; Stefano Riccio; Sergio Santamaria
Prophylactic thyroidectomy in MEN 2A syndrome.
Tumori 2003;89(5):553-5.
2003: Federica Pallotti; Ettore Seregni; Leonardo Ferrari; Antonia Martinetti; Donatella Biancolini; Emilio Bombardieri
Diagnostic and therapeutic aspects of iatrogenic hypoparathyroidism.
Tumori 2003;89(5):547-9.
2003: Leonardo Ferrari; Donatella Biancolini; Ettore Seregni; Gianluca Aliberti; Antonia Martinetti; Carlo Villano; Federica Pallotti; Carlo Chiesa; Emilio Bombardieri
Critical aspects of immunoradiometric thyroglobulin assays.
Tumori 2003;89(5):537-9.
2003: Emilio Bombardieri; Ettore Seregni; Carlo Villano; Gianluca Aliberti; Franco Mattavelli
Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.
Tumori 2003;89(5):533-6.
2003: Antonia Martinetti; Nicoletta Zilembo; Leonardo Ferrari; Giorgio Massimini; Anna Polli; Ignazia La Torre; riccardo giovanazzi; Paola Pozzi; Paolo Bidoli; Daniela De Candis; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
Anticancer research 2003;23(4):3485-91.
2003: Leonardo Ferrari; Emilio Bajetta; Antonia Martinetti; Luigi Celio; Raffaella Longarini; Ignazia La Torre; Roberto Buzzoni; Luca Gattinoni; Ettore Seregni; Emilio Bombardieri
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
International journal of oncology 2003;22(5):1081-9.
2003: Emilio Bombardieri; Ettore Seregni; Giordano Savelli; Carlo Villano; Maria Rita Castellani; F Cirillo; Federica Pallotti; S Fracassi; Carlo Chiesa; Arturo Chiti; Emilio Bajetta
Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Journal of endocrinological investigation 2003;26(8 Suppl):63-9.
2002: Antonia Martinetti; Ettore Seregni; C Ripamonti; Leonardo Ferrari; F De Conno; Rosalba Miceli; Federica Pallotti; Angela Coliva; Donatella Biancolini; Emilio Bombardieri
Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate.
The International journal of biological markers 2002;17(4):253-8.
2002: Nicoletta Zilembo; Luigi Mariani; Antonia Martinetti; Rosalba Miceli; Ettore Seregni; Ettore Bichisao; Ignazia La Torre; Paola Pozzi; Leonardo Ferrari; Daniela De Candis; V R Longarini; Emilio Bajetta; Emilio Bombardieri
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients.
Breast (Edinburgh, Scotland) 2002;11(4):286-94.
2002: Emilio Bajetta; Antonia Martinetti; Nicoletta Zilembo; Paola Pozzi; Ignazia La Torre; Leonardo Ferrari; Ettore Seregni; Raffaella Longarini; G Salvucci; Emilio Bombardieri
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1059-66.
2002: Ettore Seregni; maura massimino; S Nerini-Molteni; Federica Pallotti; B van der Hiel; Graziella Cefalo; Filippo Spreafico; F Fossati; Emilio Bombardieri
Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors.
The International journal of biological markers 2002;17(2):112-8.
2002: Emilio Bajetta; Leonardo Ferrari; Giuseppe Procopio; laura catena; Erminia Ferrario; Antonia Martinetti; Maria Di Bartolomeo; Roberto Buzzoni; Luigi Celio; Milena Vitali; Elena Beretta; Ettore Seregni; Emilio Bombardieri
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):614-21.
2002: Leonardo Ferrari; Antonia Martinetti; Nicoletta Zilembo; Paola Pozzi; Roberto Buzzoni; Ignazia La Torre; Luca Gattinoni; laura catena; Milena Vitali; Luigi Celio; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
The Journal of steroid biochemistry and molecular biology 2002;80(4-5):411-8.
2001: Emilio Bombardieri; Marco Maccauro; Maria Rita Castellani; Arturo Chiti; Giuseppe Procopio; Emilio Bajetta; Ettore Seregni
[Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?].
Minerva endocrinologica 2001;26(4):197-213.
2001: M Greco; Flavio Crippa; Roberto Agresti; Ettore Seregni; Alberto Gerali; riccardo giovanazzi; A Micheli; S Asero; C Ferraris; M Gennaro; E Bombardieri; N Cascinelli
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Journal of the National Cancer Institute 2001;93(8):630-5.
2001: S Nerini-Molteni; Ettore Seregni; Flavio Crippa; Lorenzo Maffioli; C Botti; Emilio Bombardieri
Uptake of tritiated thymidine, deoxyglucose and methionine in three lung cancer cell lines: deoxyglucose uptake mirrors tritiated thymidine uptake.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2001;22(2):92-6.
2001: Ettore Seregni; Leonardo Ferrari; Emilio Bajetta; Antonia Martinetti; Emilio Bombardieri
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12 Suppl 2():S69-72.
2000: Antonia Martinetti; Leonardo Ferrari; Luigi Celio; Luigi Mariani; Rosalba Miceli; Nicoletta Zilembo; Maria Di Bartolomeo; Luisa Toffolatti; Paola Pozzi; Ettore Seregni; Emilio Bombardieri; Emilio Bajetta
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
The Journal of steroid biochemistry and molecular biology 2000;75(1):65-73.
2000: C Botti; Ettore Seregni; Sylvie Ménard; P Collini; Elda Tagliabue; Manuela Campiglio; B Vergani; Cristina Ghirelli; Piera Aiello; Silvana Pilotti; Emilio Bombardieri
Two novel monoclonal antibodies against the MUC4 tandem repeat reacting with an antigen overexpressed by lung cancer.
The International journal of biological markers 2000;15(4):312-20.
2000: S Mattioli; Ettore Seregni; L Caperna; C Botti; Giordano Savelli; Emilio Bombardieri
BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
The International journal of biological markers 2000;15(3):219-25.
2000: Lorenzo Maffioli; Ettore Seregni; Carlo Chiesa; S Nerini-Molteni; Alberto Gerali; Emilio Bombardieri; Marco Greco; Roberto Agresti
Detection of lymph node metastases by lymphoscintigraphy with a tumour-seeking tracer in breast cancer patients.
European journal of nuclear medicine 2000;27(6):744-6.
2000: Maria Rita Castellani; Arturo Chiti; Ettore Seregni; Emilio Bombardieri
Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2000;44(1):77-87.
2000: Ettore Seregni; Leonardo Ferrari; M Stivanello; Luigi Dogliotti
Laboratory tests for neuroendocrine tumours.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2000;44(1):22-41.
1999: Arturo Chiti; BJ Van Graafeiland; Giordano Savelli; Leonardo Ferrari; Ettore Seregni; Maria Rita Castellani; Emilio Bombardieri
Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Italian journal of gastroenterology and hepatology 1999;31 Suppl 2():S190-4.
1999: Emilio Bajetta; Leonardo Ferrari; Antonia Martinetti; Luigi Celio; Giuseppe Procopio; Salvatore Artale; Nicoletta Zilembo; Maria Di Bartolomeo; Ettore Seregni; Emilio Bombardieri
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Cancer 1999;86(5):858-65.
1999: Paolo Foa; Monica Fornier; Rosalba Miceli; Ettore Seregni; Luigi Santambrogio; Mario Nosotti; I Cataldo; M Sala; S Caldiera; Emilio Bombardieri
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Anticancer research 1999;19(4C):3613-8.
1999: Leonardo Ferrari; Ettore Seregni; Emilio Bajetta; Antonia Martinetti; Emilio Bombardieri
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Anticancer research 1999;19(4C):3415-27.
1999: Luigi Celio; Antonia Martinetti; Leonardo Ferrari; Roberto Buzzoni; Luigi Mariani; Rosalba Miceli; Ettore Seregni; Giuseppe Procopio; Antonio Cassata; Emilio Bombardieri; Emilio Bajetta
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Anticancer research 1999;19(3B):2261-8.
1999: Paolo Foa; Monica Fornier; Rosalba Miceli; Ettore Seregni; Luigi Santambrogio; Mario Nosotti; S Massaron; I Cataldo; Sabina Oldani; A Iurlo; S Caldiera; Emilio Bombardieri
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
The International journal of biological markers 1999;14(2):92-8.
1999: Ettore Seregni; C Botti; E Bajetta; Leonardo Ferrari; Antonia Martinetti; S Nerini-Molteni; Emilio Bombardieri
Hormonal regulation of MUC1 expression.
The International journal of biological markers 1999;14(1):29-35.
1999: SN Molteni; Ettore Seregni; C Botti; Antonia Martinetti; Leonardo Ferrari; Flavio Crippa; Emilio Bombardieri
The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation.
Anticancer research 1999;19(1A):255-9.
1998: Flavio Crippa; Ettore Seregni; Roberto Agresti; Carlo Chiesa; Claudio Pascali; Anna Bogni; D Decise; V De Sanctis; Marco Greco; M G Daidone; Emilio Bombardieri
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.
European journal of nuclear medicine 1998;25(10):1429-34.
1998: Danila Coradini; Elia Biganzoli; Patrizia Boracchi; Emilio Bombardieri; Ettore Seregni; Giuseppe De Palo; Gabriele Martelli; Giovanni Di Fronzo
Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
International journal of cancer. Journal international du cancer 1998;79(4):305-11.
1998: Emilio Bajetta; Lorenza Rimassa; Carlo Carnaghi; Ettore Seregni; Leonardo Ferrari; Maria Di Bartolomeo; Enrico Regalia; Antonio Cassata; Giuseppe Procopio; Luigi Mariani
5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Cancer 1998;83(2):372-8.
1998: Ettore Seregni; Arturo Chiti; Emilio Bombardieri
Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results.
European journal of nuclear medicine 1998;25(6):639-58.
1998: Antonia Martinetti; Ettore Seregni; Filiberto Belli; Arabella Mazzocchi; Roberto Agresti; Natale Cascinelli; M Greco; Emilio Bombardieri
Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Anticancer research 1998;18(3B):2027-30.
1998: Ettore Seregni; S Massaron; Antonia Martinetti; M T Illeni; D Rovini; Filiberto Belli; Roberto Agresti; M Greco; Natale Cascinelli; Emilio Bombardieri
S100 protein serum levels in cutaneous malignant melanoma.
Oncology reports 1998;5(3):601-4.
1998: C Botti; Ettore Seregni; Leonardo Ferrari; Antonia Martinetti; Emilio Bombardieri
Immunosuppressive factors: role in cancer development and progression.
The International journal of biological markers 1998;13(2):51-69.
1998: Leonardo Ferrari; Ettore Seregni; Antonia Martinetti; BJ Van Graafeiland; S Nerini-Molteni; C Botti; Salvatore Artale; S Cresta; Emilio Bombardieri
Chromogranin A measurement in neuroendocrine tumors.
The International journal of biological markers 1998;13(1):3-9.
1998: S Massaron; Ettore Seregni; R Luksch; Michela Casanova; C Botti; Leonardo Ferrari; Antonia Martinetti; SN Molteni; Franca Fossati Bellani; Emilio Bombardieri
Neuron-specific enolase evaluation in patients with neuroblastoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(4):261-8.
1998: Flavio Crippa; Roberto Agresti; Ettore Seregni; Marco Greco; Claudio Pascali; Anna Bogni; Carlo Chiesa; V De Sanctis; V Delledonne; Bruno Salvadori; M Leutner; Emilio Bombardieri
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(1):4-8.
1998: Emilio Bombardieri; Ettore Seregni; Maria Grazia Daidone; E Benini; S Massaron; Leonardo Ferrari; Giovanni Di Fronzo; R Silvestrini
P53 accumulation in primary breast cancer: a comparison between immunohistochemistry and a novel luminometric immunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(1):12-8.
1997: Emilio Bajetta; Leonardo Ferrari; Luigi Celio; Luigi Mariani; Rosalba Miceli; A Di Leo; Nicoletta Zilembo; Roberto Buzzoni; I Spagnoli; Antonia Martinetti; Ettore Bichisao; Ettore Seregni
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
The Journal of steroid biochemistry and molecular biology 1997;63(4-6):261-7.
1997: Emilio Bombardieri; Antonia Martinetti; Rosalba Miceli; Luigi Mariani; Maria Rita Castellani; Ettore Seregni
Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
European journal of nuclear medicine 1997;24(11):1349-55.
1997: C Botti; Ettore Seregni; S Mattioli; Antonia Martinetti; Leonardo Ferrari; Emilio Bombardieri
Bladder cancer monitoring using two novel urinary markers.
The International journal of biological markers 1997;12(4):174-80.
1997: Lorenzo Maffioli; Ettore Seregni; S Nerini-Molteni; S Massaron; Flavio Crippa; Emilio Bombardieri
Breast cancer seeking agents: basic approach.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1997;41(3):211-24.
1997: Antonia Martinetti; Ettore Seregni; Emilio Bajetta; G F Bolelli; Leonardo Ferrari; S Massaron; C Botti; Emilio Bombardieri
Development of a rapid and ultrasensitive RIA method for estrogen (E2, E1, E1-S) determination with selective solid phase extraction.
The International journal of biological markers 1997;12(3):102-5.
1997: Ettore Seregni; C Botti; S Massaron; C Lombardo; A Capobianco; Anna Bogni; Emilio Bombardieri
Structure, function and gene expression of epithelial mucins.
Tumori 1997;83(3):625-32.
1997: E Bombardieri; L Ferrari; A Spinelli; Lorenzo Maffioli; Ettore Seregni; G Buraggi
Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: biological basis, present status and future perspectives.
Anticancer research 1997;17(3B):1719-29.
1997: C Botti; DR Negri; Ettore Seregni; V Ramakrishna; Flavio Arienti; Lorenzo Maffioli; C Lombardo; Anna Bogni; Claudio Pascali; Flavio Crippa; S Massaron; F Remonti; S Nerini-Molteni; Silvana Canevari; Emilio Bombardieri
Comparison of three different methods for radiolabelling human activated T lymphocytes.
European journal of nuclear medicine 1997;24(5):497-504.
1997: Emilio Bombardieri; S Massaron; Antonia Martinetti; Ettore Seregni
Cost-effectiveness of tumor marker detection in cancer patients.
The International journal of biological markers 1997;12(2):47-8.
1997: Ettore Seregni; C Botti; S Massaron; Antonia Martinetti; Leonardo Ferrari; SN Molteni; Emilio Bombardieri
Mucinous markers in breast cancer.
Tumori 1997;83(2):550-1.
1997: Lorenzo Maffioli; Ettore Seregni; Arturo Chiti; SN Molteni; Flavio Crippa; C Botti; Anna Bogni; Roberto Agresti; Emilio Bombardieri
Radiopharmaceuticals for breast cancer imaging.
Tumori 1997;83(2):512-4.
1997: Antonia Martinetti; Emilio Bajetta; Ettore Seregni; Nicoletta Zilembo; Leonardo Ferrari; C Noberasco; S Massaron; Lorenza Rimassa; Emilio Bombardieri
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(4):197-205.
1997: C Botti; Ettore Seregni; Sylvie Menard; Elda Tagliabue; A Bonanate; D Cantarella; C Lombardo; S Massaron; Antonia Martinetti; Leonardo Ferrari; Cristina Ghirelli; Piera Aiello; Emilio Bombardieri
Production of a novel monoclonal antibody against MUC4 mucin.
The International journal of biological markers 1997;12(1):42-3.
1997: C Botti; Ettore Seregni; C Lombardo; S Massaron; Emilio Bombardieri
Effects of steroid-free fetal serum and steroid supplementation on MUC1 gene expression in human breast cancer cell line MCF7.
Anticancer research 1997;17(1A):205-8.
1996: R Mione; Giuseppe Aimo; Emilio Bombardieri; A Cianetti; Mario Correale; P Barioli; M Barichello; Carlo Terrone; S Massaron; Ettore Seregni; D Marzano; Ines Abbate; Arcangelo Pagliarulo; Massimo Gion
Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study.
Tumori 1996;82(6):543-9.
1996: Ettore Seregni; C Botti; C Lombardo; A Cantoni; Anna Bogni; I Cataldo; Emilio Bombardieri
Pattern of mucin gene expression in normal and neoplastic lung tissues.
Anticancer research 1996;16(4B):2209-13.
1996: Ettore Seregni; C Botti; G Ballabio; Emilio Bombardieri
Biochemical characteristics and recent biological knowledge on prostate-specific antigen.
Tumori 1996;82(1):72-7.
1995: Emilio Bombardieri; Arturo Chiti; Flavio Crippa; Ettore Seregni; I Cataldo; Lorenzo Maffioli; E Soresi
111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1995;39(4 Suppl 1):104-7.
1995: Ettore Seregni; C Botti; Emilio Bombardieri
Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms.
Anticancer research 1995;15(4):1491-9.
1995: Emilio Bombardieri; Flavio Crippa; I Cataldo; Arturo Chiti; Ettore Seregni; E Soresi; R Boffi; G Invernizzi; G L Buraggi
Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy.
European journal of cancer (Oxford, England : 1990) 1995;31A(2):184-8.
1995: Ettore Seregni; C Botti; Anna Bogni; Emilio Bombardieri
Tumour marker evaluation in patients with lung cancer.
Scandinavian journal of clinical and laboratory investigation. Supplementum 1995;221():67-71.
1995: Flavio Crippa; Giorgio Bolis; Ettore Seregni; N Gavoni; Giovanna Scarfone; C Ferraris; G L Buraggi; Emilio Bombardieri
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):686-90.
1994: Lorenzo Maffioli; Luigi Mascheroni; Valeria Mongioj; Massimo Gasparini; M T Baldini; Ettore Seregni; Maria Rita Castellani; N Cascinelli; G L Buraggi
Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(11):1741-7.
1994: Emilio Bombardieri; Ettore Seregni; C Lombardo; A Cantoni; Anna Bogni; C Botti; L Sfreddo; I Cataldo
Mucin gene expression in lung cancer tissues.
The International journal of biological markers 1994;9(4):262-3.
1994: Ettore Seregni; R Luksch; Flavio Crippa; G F Bruni; E Bombardieri
Evaluation of serum osteocalcin and myosin in pediatric patients affected by osteosarcoma and rhabdomyosarcoma.
The International journal of biological markers 1994;9(4):260-1.
1994: Emilio Bombardieri; Ettore Seregni; Anna Bogni; S Ardit; S Belloli; A Busetto; B Caniello; M Castelli; A Cianetti; Mario Correale
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial.
The International journal of biological markers 1994;9(2):89-95.
1993: Anna Bogni; Ettore Seregni; C Botti; Paolo Foa; I Cataldo; Flavio Crippa; Emilio Bombardieri
EIA/IRMA test for cytokeratin 19 determination.
The International journal of biological markers 1993;8(3):200-1.
1993: Flavio Crippa; Ettore Seregni; Roberto Agresti; Emilio Bombardieri; G L Buraggi
Bone scintigraphy in breast cancer: a ten-year follow-up study.
Journal of nuclear biology and medicine (Turin, Italy : 1991) 1993;37(2):57-61.
1993: Ettore Seregni; Flavio Crippa; C Botti; M G Bellotti; Anna Bogni; M Pizzichetta; Emilio Bombardieri
Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
The International journal of biological markers 1993;8(2):124-9.
1993: A Bogni; Ettore Seregni; A V Abregú; R Boni; E Bombardieri
PSA-alpha 1-antichymotrypsin determination in patients with benign prostatic hyperplasia and prostatic cancer.
The International journal of biological markers 1993;8(2):138-9.
1992: G L Buraggi; M Gasparini; Ettore Seregni; Emilio Bombardieri; Enrico Regalia; Lorenzo Maffioli
Pilot, multicenter and prospective trials with an anti-CEA antibody.
The International journal of biological markers 1992;7(3):189-92.
1992: Ettore Seregni; Emilio Bombardieri; Anna Bogni; Flavio Crippa; E De Jager; G L Buraggi
The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan.
The International journal of biological markers 1992;7(3):167-70.
1992: C Colombo; M R Castellani; W F Balistreri; Ettore Seregni; M L Assaisso; Annamaria Giunta
Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease.
Hepatology (Baltimore, Md.) 1992;15(4):677-84.
1992: M Pizzichetta; Anna Bogni; Ettore Seregni; Lorenzo Maffioli; E de Jager; A Costa; Emilio Bombardieri
CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years.
The International journal of biological markers 1992;7(1):59-60.
1992: Flavio Crippa; Emilio Bombardieri; Ettore Seregni; Maria Rita Castellani; M Gasparini; Lorenzo Maffioli; M Pizzichetta; G L Buraggi
Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.
Journal of nuclear biology and medicine (Turin, Italy : 1991) 1992;36(1):52-5.
1992: Emilio Bombardieri; M Pizzichetta; Paolo Veronesi; Ettore Seregni; Anna Bogni; Lorenzo Maffioli; G S Jotti; M A Bassetto; Stefano Zurrida; A Costa
CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):144-6.
1991: G L Buraggi; M Gasparini; Ettore Seregni
Immunoscintigraphy of colorectal carcinoma with an anti-CEA monoclonal antibody: a critical review.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(1):45-50.
1991: Francesco Boccardo; E Bombardieri; S Zanardi; G Valenti; FLAVIA ZANABONI; M Valtolina; Ettore Seregni; Flavio Crippa
Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
The International journal of biological markers 1991;6(1):12-20.
1991: Flavio Crippa; G L Buraggi; E Di Re; M Gasparini; Ettore Seregni; Silvana Canevari; M Gadina; Mauro Presti; A Marini; E Seccamani
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.
European journal of cancer (Oxford, England : 1990) 1991;27(6):724-9.
1990: Ettore Seregni; Emilio Bombardieri; Lorenzo Maffioli; G L Buraggi
Mucinic tumor markers recognized by monoclonal antibodies.
The Journal of nuclear medicine and allied sciences 1990;34(4):314-20.
1989: Ettore Seregni; Giordano Savelli; Emilio Bombardieri
Alpha-fetoprotein (AFP) in germ cell tumors of the testis.
The Journal of nuclear medicine and allied sciences 1989;33(3 Suppl):42-5.
1988: M Gasparini; M Ripamonti; Ettore Seregni; Enrico Regalia; G L Buraggi
Tumor imaging of colo-rectal carcinoma with an anti-CEA monoclonal antibody.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1988;2():81-4.
1986: G Buraggi; A Turrin; N Cascinelli; A Attili; M Gasparini; L Callegaro; S Ferrone; Ettore Seregni; Emilio Bombardieri; F Belli
Radioimmunodetection of melanoma: preliminary results of a prospective study.
The International journal of biological markers 1986;1(1):47-54.
1985: Emilio Bombardieri; G S Jotti; M G Cocciolo; M Mori; A Rusconi; M Rusca; Ettore Seregni; G Becchi; M Fontanesi; A Tardini
Tissue polypeptide antigen and carcinoembryonic antigen in colon tumors: serum levels and immunohistochemical localization.
Cancer detection and prevention 1985;8(1-2):219-26.